Nathan Higginson Scott
About Nathan Higginson Scott
Chief Technology Officer Nathan Higginson-Scott
Nathan Higginson-Scott is the Chief Technology Officer with extensive experience in creating innovative biologics drugs and drug technologies. Over a career spanning more than 15 years, he has made notable contributions both in academia and the industry. Nathan’s expertise encompasses a broad range of areas, including antibody technology, molecular immunology, and preclinical stage projects.
Nathan Higginson-Scott's Role at Pandion Therapeutics
At Pandion Therapeutics, Nathan Higginson-Scott served as the Vice President of Biotherapeutics. During his tenure, he significantly contributed to the company’s growth from its inception in 2017 through various successful financing rounds. Nathan played an instrumental role in the upsized IPO and the eventual acquisition of Pandion by Merck for $1.85 billion in 2021. His efforts in biotherapeutic development and corporate strategy were pivotal to Pandion’s success.
Nathan Higginson-Scott's Career at Pfizer
Nathan Higginson-Scott held several important positions at Pfizer, where he co-invented a proprietary bispecific platform. At Pfizer, he led an antibody optimization group and oversaw numerous technology development, drug discovery, and preclinical stage projects across various therapeutic areas, including inflammation and immunology. His work at Pfizer exemplifies his commitment to advancing therapeutic technologies and drug development.
Nathan Higginson-Scott's Contributions to Verily Life Sciences
During his time at Google[x], Nathan Higginson-Scott contributed to the launch of Verily Life Sciences. He played a key role in developing antibody-based capabilities designed to support a diagnostic nanoparticle platform. His work at Verily Life Sciences demonstrates his ability to integrate advanced technologies with life sciences for innovative healthcare solutions.
Nathan Higginson-Scott's Educational Background
Nathan Higginson-Scott began his career in antibody technology and molecular immunology at Imperial College London. Supported by a prestigious Wellcome Trust grant, he completed his Ph.D., focusing on developing bi-paratopic antibodies using phage display. His academic background laid the foundation for his ongoing contributions to biologics drug development and innovative drug technologies.
Nathan Higginson-Scott's Community and Volunteer Work
Nathan Higginson-Scott co-founded the Massachusetts chapter of a Pfizer Colleague Resource Group for LGBTQ+ employees and allies. He also facilitated Pandion’s participation in Boston Pride. Additionally, he volunteers weekly as a suicide and crisis intervention counsellor for The Trevor Project, supporting LGBTQ+ youth in crisis. His commitment to community service and advocacy underscores his dedication to making a positive impact beyond his professional accomplishments.